Definitive Healthcare price target lowered to $2 from $3 at Stephens

Stephens lowered the firm’s price target on Definitive Healthcare (DH) to $2 from $3 and keeps an Equal Weight rating on the shares. Turnaround efforts should drive Life Sciences revenue back to growth, but the firm sees the timing as uncertain, the analyst tells investors.